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INTRODUCTION
Human immunodeficiency virus (HIV) infection is
caused by HIV-1 and HIV-2 which are members of
the Lentivirus subfamily of retroviruses. They are
slow acting in comparism with other acute virus
infections. It is the cause of the acquired immune
deficiency syndrome(AIDS).This infection has
reached pandemic proportion with sub Saharan
Africa being the worst hit. In Eastern and Southern
Africa the prevalence ranges from 9% in males to
34% in females, while in Nigeria, West Africa, the
prevalence is 3.9% in adults aged 15-49 and 4.4% in
the population.
The HIV/AIDS pandemic has affected the
prevalence of several diseases notable amongst
which are tuberculosis , toxoplasmosis , superficial
and deep mycosis etc. Hepatitis C (HCV)formerly
designated Non-A, Non-B hepatitis is a linear, single
stranded RNA virus belonging to the Flaviviridae
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transmitted sexually and parenterally and leads to
acute and chronic hepatitis, liver failure ,cirrhosis and
hepatocellular carcinoma in those infected. It is also a
very important potentially lethal and presently
treatable infection, which may affect the course and
worsen the outcome of HIV disease, even when these
patients are on adequate treatment with antiretroviral
drugs (ARVs), and may be affected by the presence of
HIV disease.
The prevalence of HCV in the developed world
appears to be lower than in the developing world. A
prevalence of 0.3% has been reported in Canada and
Northern Europe 0.6% in United States of America
and Central Europe 1.2 1.5% in Japan and southern
Europe, as compared with 3.5% to 6.4% in certain
regions in Africa. South African reports put the
prevalence at between 0-1.5%. In Nigeria, the
prevalence rate of HCV varies between 5.8-12.3%
. In Benin City it was 12.3%, in Lagos ,6%, in Ilorin,
5.8%.Literature available shows that HIV disease
affects the prevalence and prognosis of HCV
infection. The prevalence of HCV in the developed
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PREVALENCE OF HEPATITIS C VIRUS IN HIV INFECTED PERSONS IN A
TERTIARY HOSPITAL IN NIGERIA.
To assess the prevalence of hepatitis C virus (HCV) infection among HIV/AIDS patients in a
tertiary hospital in Nigeria.
All infected persons confirmed by Elisa and aged 15 years and above seen at the University of Benin
Teaching Hospital were included in the study. The subjects were recruited over a period of one year. All
patients with sickle cell anemia and other immuno compromising diseases were excluded from the study. Age
and sex matched controls were pooled from patients attending the out patient clinics of the hospital who were
HIV negatives. A medical history and complete physical examination under bright light was carried out on all
the subjects. Assays done for each of the patients were HIV screening by Elisa techniques and confirmed by
double Elisa and hepatitis C virus screening.
A total of 370 subjects were involved in the study of which 204 were cases (HIV positive patients)
while 166 were HIV negative controls. Comparing the patients who were widowed with other marital groups,
more of the widows were HIV positive than other marital groups. This difference was found to be statistically
significant (X =12.807, df = 1: P = 0.000). Nine (4.4%) HIV positive patients were found to be Hepatitis C
seropositive while 4 (2.4%) HIV negative controls were hepatitis C seropositive. There was no statistical
difference between the prevalence of Hepatitis C virus infection among HIV positive patients and the controls
(HIV negative patients)
This study has shown that there is no statistical significant difference between the prevalence of
hepatitis C virus infection in HIV positive and HIV negative patients. This is in agreement with findings in other
developing countries, in the South/South (Niger Delta) of Nigeria and other regions of Nigeria.
Prevalence, hepatitis C, HIV patients.
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persons. Among drug users it may be as high as
80%. A study in Malawi amongst pregnant women
showed that there was no statistical evidence to
suggest that HIV positively was associated with an
increased prevalence of HBV or HCV markers.
Daar and his colleagues reported that in a large
cohort of hemophilliacs, hepatitis C may accelerate
HIV disease progression and this finding was
corroborated with a Swiss Cohort study.
Sulkowski and co-workers suggested that HCV/HIV
co-infection was not associated with increased risk
of death or development of opportunistic diseases,
while Mao and colleagues did not find evidence for
increased HCV genetic substitution in early HIV
infection.
The prevalence rate of HCV is shown to be higher in
HIV infected patients than in the general population
worldwide. The prevalence of HCV in HIV
infected persons in Nigeria ranges between 0.9% in
the Niger delta to 18.3% in North central Nigeria .
This study will provide data that can be used for
further studies and useful recommendations and
policies on this subject can be formed.
Subjects for the study were recruited from the
University of Benin Teaching Hospital (UBTH).
UBTH is a tertiary healthcare facility set up in 1973.
It caters for the tertiary health care needs of patients
referred from Edo, Delta, Ekiti, Bayelsa, Kogi and
Ondo States. Its coverage serves a population of
over 5million people. The Dermatology/Venerology
unit in UBTH handles cases of sexually transmitted
diseases including HIV/AIDS referred from these
areas and even beyond. It has facilities for
diagnostic and confirmation tests for HIV/AIDS.
All HIV infected persons, confirmed by ELISA and
aged 15years and above of either gender seen in the
University of Benin Teaching Hospital were
included in the study. The subjects were recruited
over a period of one year (Ist January to 31st
December 2002). Exclusion criteria included HIV
negative patients or HIV positive patients with sickle
cell anemia and other immune compromising
diseases such as diabetes mellitus and lymphoma.
Age and sex matched controls were pooled from
patients attending the out patient clinics of the
hospitals who were HIV negative.
All HIV infected patients on presentation were
interviewed, examined, tested and included in the
study until the sample size was achieved. Pre-test
and post-test HIV counselling was administered to
all the subjects. The tests were carried out with the
informed consent of all patients. Using a prevalence
of 4% , sample size for comparative study per group
was 48. However a sample size of 204 patients (HIV
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patients) was used. Amedical history and a complete
physical examination under bright light were also
carried out. The data acquisition sheet was researcher
administered after a written consent.
Assays done for each of the patients were
1. HIV screening by ELISAtechniques and confirmed
by double ELISA
2. Hepatitis C virus screening
Fasting blood sugar and Hemoglobin electrophoretic
pattern were used to rule out diabetes and sickle cell
anemia. Full blood counts, electrolytes and urea and
liver function tests were also done.
Determine test kit by Abbot was used. It is an
immunochromatographic test for the qualitative
immunoassay for the detection of antibodies to HIV- 1
and HIV 2 in human serum, plasma or whole blood. It
was used in parallel with STAT-PAK by CHEMBIO
diagnostics inc. Where results were indeterminate,
GENIE II by BIO-RAD was used to break the tie. The
principles and procedures of these tests are similar.
GENIE II is a dual recognition immunochrom-
atography and immunoconcentration test.
Sample is added to the sample pad. As it migrates
through the conjugate pad, it reconstitutes and mixes
with the selenium colloid antigen conjugate.This
mixture continues to migrate through the solid phase
to the immobilized recombinant antigens and
synthetic peptides at the patients' window site. If
antibodies to HIV -1 and or HIV- 2 are present in the
sample, they bind to the antigen selinium colloid and
to the antigen at the patient window, forming a red or
pink/purple line at the patient window site. If not
present no red line is formed.
Human serum plasma or whole blood was collected
by venupuncture in an aseptic manner in such a way to
prevent hemolysis. For serum and plasma samples,
50ul of samples using a precision pipette for
Determine, 5ul for STAT-PAK was dropped on the
sample pad. Fifteen to sixty minutes (15-60minutes)
after, the result was read for Determine test, STAT-
PAK results were read in 10 minutes.
In a positive Determine test, 2 red bars appear in the
control window and in the patent window of the strip.
When only one bar appears in the control window, it is
negative. It is invalid if no bar appears. STAT-PAK is
positive when two pink/purple lines appear one in the
test area one in the control area and invalid when none
appears.
The test was done using Clininotech (Clini-Tech
Diagnostic pharmaceuticals Canada) anti HCV
cassette which is a rapid direct binding procedure,
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infection. This test is primarily based on the
principle of double antigen sandwich immunoassay
in which purified recombinant antigens are
employed sufficiently to identify anti-HCV with
high sensitivity and specificity.
Anticoagulant is not required in serum collection.
The blood was allowed to clot and the serum
separated from the clot, which was then used for
testing. The serum was stored in fridge or freezer if
not used that day and brought to room temp prior to
testing.
The test device was removed from its pouch, it was
then dipped into fresh serum specimen for 2-3
seconds with the arrow end pointing down. It was
then laid flat on a clean dry non-absorbent surface
(test bench)
Results were read within 10 20 minutes depending
on the concentration of Anti HCV in serum. After
30minutes results were considered invalid. A
positive result shows 2 distinct red bands on the
positions indicated T (test) and C (control). A single
band at ' C' indicated a negative result. All tests were
carried out at room temp and at least 2 people
visualized the test bands in a well-lit laboratory.
The data were analysed using the EPI-INFO 2000
statistical program version 6.0 and PEPI version 3.
Continuous variables were described with means
while discontinuous variables were described with
proportions. When comparing groups of subjects,
the X (Chi square) test was applied to determine the
significance of the difference observed.
A total of 370 subjects were involved in the study.
Two hundred and four (204) were HIV positive
patients while another 166 were HIV negative
controls. The two groups of patients in the study
were comparable as regards age and sex. (Table1).
Amongst the HIV positive patients, 81 (39.7%) were
males and 123 (60.3%) were females with a mean
age of 37.14± 10.94 and an age range of 15- 70 years.
For the controls, 66 (39.8%) of them were males,
while 100 (60.2%) were females with a mean age of
37.21± 11.4 and range of 15-70. There is no
significant age and sex difference between HIV
positive patients and controls (P>0.05) (Table 1).
All patients were recruited into the study prior to the
commencement of anti retroviral therapy. (Table 1)
Table 2 shows the clinical staging of HIV patients
used in the study. A total of 145 (71.1%) were
asymptomatic. 56 (69.1%) of them were males while
89 (72.4 %) were females. 2 (1.0%) had persistent
generalized lymphadenopathy, and were both males.
57 (27.9 %) patients had full blown AIDS, 23
(28.4%) of whom were males while 34




(27.6 %) were females.
Table 3 shows the distribution of the HIV positive
patients and the HIV negative controls according to
marital status. (Table 3) Among the HIV positive
patients, 5 (2.5%) were divorced, 116 (56.9%)
married, 5 (2.5%) separated, 58 (28.4%) single and
20 (9.8%) were widowed. Among the HIV negative
patients (control group), none was divorced or
separated, 110 (66.3%) were married, 55 (33.1%)
were single, while 1 (0.6%) was widowed.
Comparing the widowed group with the other marital
groups, more of the widows were HIV positive then
other marital groups. This difference was found to be
statistically significant. (X = 12.807, df = 1: P= 0.000
[3.45E-04] Table 4.
Comparing the divorced patients with other marital
groups, all 5(100.0%) were HIV positive, while none
was HIV negative. For the other marital groups, 199
(54.5%) were HIV positive, while 166 (45.5%) were
HIV negative. This difference was found to be
statistically significant using Likelihood ratio Chi-
square (X = 2.943, df = 1; P=0.086). (Table 4)
Comparing married group with unmarried (single,
divorced, separated and widowed) group, 116
(51.3%) were found to HIV positive, while 110
(48.7%) were found to be HIV negative. Among the
unmarried group 88 (61.1%) were found to be HIV
negative, while 56 (38.9%) were found to be HIV
negative. This difference was not found to be
statistically significant (X = 3.421, df = 1: P = 0.064).
(Table 4)
Table 5 shows the prevalence of Hepatitis C virus
infection amongst HIV seropositive patients
compared to HIV seronegative patients. 9 (4.4%)
HIV positive patients were found to be Hepatitis C
seropositive, while 4 (2.4%) HIV negative controls
were hepatitis C seropositive. This difference was
not found to be statistically significant (Likelihood






Age and Sex Data of Patients and Controls.
Demographic HIV Positive HIV Negative
Data Patients Patients (Controls)
Sex
Male 81 (39.7%) 66 (39.8%)
Female 123 (60.3%) 100 (60.2%)
Total 204 (100.0%) 166 (100.0%)
Age (years)
Mean age 37.14 37.21
Standard deviation 10.94 11.30
Range 15-70 15-70
Hepatitis C HIV+ (%) HIV-(%) Total
Sero-status
Hepatitis C+ 9(4.4) 4(2.4) 13(3.5)
Hepatitis C- 195(95.6) 162(97.6) 357(96.5)







Likelihood ratio Chi- square with Yates's correction
= 0.584, df = 1: P= 0.45)
Clinical Staging of HIV Positive Patients.
Marital Status of HIV Positive Patients
(HIV+) and Controls (HIV-).
Marital Status of HIV Positive Patients
(HIV+) and Controls (HIV-).





HIV status Marital status (N = 370) X2 df P
Divorced Other Marital groups
HIV+ 5 (100.0%) 199(54.5%)
HIV- 0 (0.0%) 166(45.5%)
Total 5 (100%) 365(100%) 2.943 1 0.086
Widowed Other Marital groups
HIV+ 20(95.2%) 184(52.7%)




HIV- 110(48.7%) 56(38.9%) 3.421 1 0.064
Total 226(100%) 144(100%)








The prevalence of hepatitis C infection among HIV
positive patients in this study was found to be 4.4%,
while among HIV negative (controls) patients was
2.4%. Though there was a higher prevalence among
the HIV positive patients, this difference was not
found to be statistically significant. (X = 0.584, df =
1: P=0.445)
The prevalence rates of hepatitis C infection in both
the controls and patient were higher than the findings
in the developed world Canada and Northern Europe
(0.3%) , United States ofAmerica and Central Europe
(0.6%) , Southern Europe and Japan (1.2 -1.5%) but
similar to that in certain regions in Africa (3.5
6.4%) . In Nigeria, the prevalence ranges from 5.8-
12.3% it is 0,9-18.3% amongst HIV infected
persons This study corroborates the fact that the
prevalence of Hepatitis C infection is higher among
the developing then the developed countries. Among
HIV infected patients, the prevalence of HCV seem to
be higher in the developed countries (38-43%) than
the findings of this study (4.4%). This is the case
among drug users in the developed countries (80%).
This may be explained by the fact that in sub-Saharan
Africa, the major route of HIV transmission is
Heterosexual contact. This route is not a major route
for Hepatitis C transmission. HCV is most
frequently transmitted via blood transfusion (83%),
organ transplanted (78%), vertical transmission
(6.2%) and needle stick injury (6.1%) However in
the developed world, HIV is co-transmitted with
HCV during intravenous drug abuse, and
homosexual intercourse which are major routes of
HIV transmission.
Imarengiaye and his collegues in their study on the
risk of transfusion transmitted hepatitis C virus in a
tertiary hospital found at the University of Benin
Teaching Hospital, Edo State, Nigeria, a 3%
frequency of HCV among transfused units of Whole
blood . This is similar to the findings of this study.
This also compares with other studies done in Nigeria
where the prevalence ranges from 5.8-12.3% and 0.9-
18.3% in HIV infected patients. The finding of
4.4% in this study is within this range.
An interesting finding of this study was that all the
divorced patients were HIV positive. This difference
was found to be statistically significant when the
divorced patients were compared with other marital
groups using, Likelihood ratio Chi- square (X =
2.943, df = 1; P=0.086). This could be as a result of
the fact the being divorced exposed them to irregular
sexual partners or their (former) spouses being HIV
positive. The prevalence of HCV in Nigeria is not
known but data from other countries indicate that the
virus increases morbidity and mortality. HCV
infection runs a chronic course. It may be












Clinical stage Male Female Total (%)
Asymptomatic, generalized 0 0 (0%) 0 (%)
Iympadenopathy (Stage I)
Weight loss<10%, prurigo, fungal 56 (69.1%) 89 (72.4%) 145(71.1%)
Nail infection, H.zoster*, recurrent
URTI ( stage II)
Weight loss >10%, chronic diarrhea, 2 (2.5%) 0 (0.0%) 2 (1.0%)
Fever, oral candidiasis/HL*, PTB*,
Severe bacterial infections (stage III)
AIDS- defining illnesses (stageIV) 23 (28.4%) 34 (27.6%) 57 (27.9%)
Total 81 (100%) 123 (100%) 204 (100%)
44Nigerian Journal of Clinical Practice March 2010, Vol.13(1) Prevalence of Hepatitis C Virus in HIV Eze et al
disease. HCV infection is an important cause of
chronic liver disease, transplants and liver
carcinoma in developed countries where screening
is routinely done. This underscores the need for
institution of routine screening in centres in Nigeria
especially blood transfusion units and maternities.
The advent of HIV/AIDS which worsens HCV
disease progression is also a very important reason
for routine screening of HCV in institutions. This
will serve as an effective preventive strategy.
This study investigated the prevalence of HCV in
HIV/AIDS patients. The results indicate that HCV
infection is 4.4% amongst HIV/AIDS patients. This
underscores the need for more aggressive screening
of HCV both in this group of patients and in the
general population as the sequalae of this disease are
very severe.
The authors are grateful to all the patients who took
part in the study for their co-operation during the
collection of data.
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